Image source: Wikimedia Commons
According to a study from the University of Texas, the Pfizer / BioNTech vaccine can still target a key mutation that has emerged in two new variants of the coronavirus.
However, this is just one of many mutations found in new forms of the virus.
So, although the study is welcomed, it is not seen as definitive scientific evidence of how the vaccine will work.
New options have been discovered in the UK and South Africa.
Both options are spreading faster, and this has raised questions about the level of protection of vaccines against them.
Covid-19 vaccine: Israel leads the world in vaccination rates Covid-19: EU launches mass vaccination campaign Joe Biden sets 100 million Covid vaccinations Target for first 100 days
It is widely believed that vaccines will continue to work, but researchers are looking for evidence.
The study focuses on a mutation called N501Y, which appears in both new variants.
This is considered important because it is in this part of the virus that the first contact with the cells of our body takes place and the changes can facilitate the entry and causing of infection.
The researchers created two forms of the virus – one with and one without a mutation – and then bathed those viruses in blood samples taken from 20 patients who had been vaccinated in clinical trials.
The results of the study show that the immune system of vaccinated patients is able to remove the new mutation.
However, the emerging variant contains many mutations, the combined effects of which can help the virus evade the immune system.